Short description
Soft-tissue repair company commercializing regenerative tissue substitutes based on their proprietary Endoform® ECM Technology platform.
Description
Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to ‘unlocking regenerative healing for everybody’, Aroa’s products are developed from the Company’s proprietary Endoform® technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach.
The company was founded in February 2008 based on intellectual property relating to the use of a novel form of ECM isolated from forestomach extracellular matrix for use in tissue regeneration applications.
Aroa’s focus is delivering better healing, every day, everywhere for everybody. Aroa’s products make a meaningful impact for patients, surgeons and clinicians. Aroa delivers high quality, simple to use products that significantly improve outcomes. Aroa also believes its products should be widely accessible, affordable and change the standard of care for many patients.
Maori for ‘understanding’, Aroa is at the forefront of understanding how biology, structural form and human factors can unlock the body’s intrinsic power to heal.
Last funding
Cannot Access
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Auckland, Auckland, New Zealand, Oceania
Founded on
January 1, 2008
Exited on
July 24, 2020
Went public on
July 24, 2020
Stock symbol
ARX
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$34056 - 789030
Sign in for full access
Investors
Nopepepe, Noway Youcantaccess
Sign in for full access
Founders
Brian Ward